The FDA getting trigger happy

[The beef 675] [I'm an image] ‘I’m cool with this new drug as long as I’m not the first guy to take it’ boat.” - Jeff Hey there carnivores, Markets were down on Friday. May is not off to a hot start... And today we’re talking about the FDA getting trigger happy. Keep raging, Jeff & Jason [Image] [I'm an image] Approved! The anti-anti-vaxxers at the FDA loosened the reins this week, giving both Gilead’s remdesivir and Roche’s COVID antibody test the greenlight for “emergency use.” Is a global pandemic not an emergency? That feels a lot like an emergency... Gil-ville Gilead’s remdesivir got the [go-ahead]( as the first medicinal treatment to handle COVID symptoms after early clinical data showed signs of recovery in those treated with the drug. According to the study, the drug reduced the time taken to recover, those given the drug recovered in 11 days, compared to the 15 day standard. Despite the positive results, Gilead can’t go making it rain remdesivir all willy-nilly. Use of the "miracle drug" is limited to those hospitalized with low blood-oxygen levels, and those who need breathing support. Oh, so people who meet the [Ivan Drago standard?]( There was word that this might happen earlier last week, as the FDA teased Gilead, but now that they’ve signed off, it’s clear the FDA means business. Gilead closed down 4.8% on Friday, despite the news. Gilead share prices are up 23% on the year. I wonder why? Roche-ing ahead Roche Holding got its antibody test [greenlit]( by the FDA as well. Roche’s test helps identify the antibodies created by humans after they’ve been infected with coronavirus. The key here is that those with minimal symptoms, or those who are asymptomatic, may be identified. These tests are seen as the gateway to understanding the spread of the virus, tracking it, and allowing civilization to open back up. After all, there are only so many frozen pizzas a man can eat... Roche says its test has been 100% accurate in detecting COVID antibodies, and 99.8% accurate in ruling those antibodies out of those who haven’t gotten the virus. Of course, it did. The bottom line... Between a potential treatment and antibody tests, could the “new normal” be on the horizon? Many governments are hoping that antibody testing can be used to identify those whose bodies have already developed a way to fight the virus, and therefore could safely return to the workforce, helping buoy sputtering economies. To do that, some countries are suggesting the use of “[immunity passports](” for those who have a natural defense against the virus. Nope, no potential human rights violations to see here. [Image] Most Traders Will Be Rummaging To Find Trades On Monday [Alternate text]( Jason Bond On The Other Hand Will Be Peeling Off Profits All Thanks To This Weekend Strategy [Watch Now]( [I'm an image] ☑️ Too high. Elon Musk is back on his bullsh*t. The meme lord himself [got his tweetstorm on]( last week, firing off hot takes about selling all of his possessions and raging against the machine. But his most troublesome tweet sent shares down 10% Friday. He stated that $TSLA stock price was too high. I doubt that was approved by his in-house counsel. Tesla’s CEO has gotten into hot water in the past over his infamous “funding secured” tweet in August 2018. He even promised the SEC that he'd get all statements about Tesla’s stock prices and finances approved by legal counsel before firing off a tweet. Despite the drop in share price, sir-memes-a-lot is still within striking distance of his big $730M payday. The electric car's trailing six-month market value [stands at $99.1B](, just $1B shy of the targeted $100B, which would trigger his payout. ☑️ Buh-Bye. Softbank’s international arm [is cutting 10% of its workforce]( (about 24 employees) in an effort to ‘operate more efficiently’ (read: we kinda fudged up with that WeWork investment...ok, fine, Uber too, and now need to cut costs). The conglomerate expects wider net losses, totaling $8.4B for the year ending in March, thanks to, you guessed it, struggles with its WeWork investment. Do you see a theme here? ☑️ Mr. Bezos, c’mon down. Jeffrey Congress, as he’ll soon be dubbed, [has been asked to testify]( before the House of Representatives (f*cking nerd can’t even land a Senate inquiry) in regards to Amazon’s use of third party data. The company has previously stated in DC that it does not utilize such information for a competitive advantage. Sure, and it doesn’t clear browser history when it’s done with the family computer either... [ICYMI](, a WSJ report was released April 23, alleging that Amazon has been using independent third-party data from its sellers to help launch its own products. More than 20 former employees from Amazon’s private-label business, AmazonBasics, revealed that Amazon did, in fact, utilize third party data for such purpose, and now Congress wants to hear from the big cheese himself. ☑️ We’re sick of it. Essential employees of Target, Walmart, Wholefoods, FedEx, and other companies [had a ‘sickout’ on Friday](. Or as I call it, a three-day weekend. They protested the need to work in unsafe conditions where proper safety measures are not implemented. While it’s unclear how many participated at this point, it doesn’t seem like many followed through, based on Target’s statement that ‘these concerns have been raised by a very small minority of the 340k workforce’. But that statement might be one-sided. The effort also asked people to boycott shopping at certain mega-retailers on Friday, International Workers Day, which if I had to guess, only lead to more people going because they thought the stores would be empty. RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 Neither Raging Bull nor RagingBull.com, LLC (publisher of Raging Bull) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Raging Bull manages on behalf of RagingBull.com, LLC. If you no longer wish to receive our emails, click the link below: [Click Here to stop receiving emails from support@ragingbull.com]( [Unsubscribe from all RagingBull emails](